Logo

Boan Biotech Highlights Clinical Updates for BA6101 (biosimilar, Prolia) and BA1102 (biosimilar, Xgeva) to Treat Various Indications

Share this
Boan Biotech

Boan Biotech Highlights Clinical Updates for BA6101 (biosimilar, Prolia) and BA1102 (biosimilar, Xgeva) to Treat Various Indications

Shots:

  • The company has completed patient enrolment in P-III trial which evaluates the safety, efficacy, PK & immunogenicity of BA6101 & BA1102 vs reference drugs (Prolia & Xgeva) for the treatment of various indication across Europe, United States & Japan
  • Boan had also conducted a meeting in Germany to highlight the PK results from the P-I analysis of BA6101 vs Prolia across Europe. The study met the pre-specified acceptance criteria of bioequivalence for PK & PD along with a similarity in PK, PD, safety & immunogenicity
  • Earlier in Nov 2022, the company launched BA6101 (Boyoubei) across China and received positive feedback from doctors & patients on its clinical application. Later in Mar 2023, the NMPA accepted the BLA for BA1102

Ref: Boan Biotech | Image: Boan Biotech

Related News:- Boan Biotech Reports the Completion of Patient Enrolment in the P-III Clinical Trial of BA5101, a Proposed Biosimilar Dulaglutide

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions